MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock from...
$11,071,534
Proceeds from exercise of
warrants
$4,814,027
Proceeds from issuance of
convertible preferred stock
$990,000
Net cash provided by
financing activities
$14,733,901
Canceled cashflow
$2,141,660
Net change in cash
and cash...
$5,344,491
Canceled cashflow
$9,389,410
Payment of offering
costs for financing...
$1,771,939
Principal repayments on
finance leases
$324,346
(payments) proceeds from
loans payable
-$45,375
Fair value
adjustment on warrants
$3,810,278
Stock-based compensation
expense
$671,474
Accounts and other
receivables
-$597,242
Depreciation and
amortization
$504,836
Accrued expenses
$319,267
Unearned revenue
$18,001
Operating lease
right-of-use asset
-$1,224
Net cash used in
operating activities
-$9,328,842
Net cash used in
investing activities
-$60,568
Canceled cashflow
$5,922,322
Net loss
-$14,909,754
Purchase of property and
equipment
$60,568
Accounts payable
-$225,410
Prepaid expenses and
other assets
$90,060
Inventory
$25,940
Back
Back
Cash Flow
source: myfinsight.com
bioAffinity Technologies, Inc. (BIAFW)
bioAffinity Technologies, Inc. (BIAFW)